Carnegie Investment Counsel’s Zimmer Biomet ZBH Stock Holding History

Carnegie Investment Counsel’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,816	Closed	-$240K	–	508
2024 Q1	$240K	Buy	+1,816	New	+$227K	0.01%	448
2023 Q3	–	Sell	-1,546	Closed	-$225K	–	508
2023 Q2	$225K	Sell	1,546 -200	-11%	-$27.2K	0.01%	455
2023 Q1	$226K	Sell	1,746 -1	-0.1%	-$126	0.01%	476
2022 Q4	$223K	Buy	+1,747	New	+$203K	0.01%	470
2017 Q1	–	Sell	-2,401	Closed	-$242K	–	355
2016 Q4	$242K	Hold	2,401	–	–	0.03%	293
2016 Q3	$296K	Hold	2,401	–	–	0.04%	256
2016 Q2	$288K	Buy	2,401 +378	+19%	+$42.8K	0.04%	266
2016 Q1	$206K	Buy	+2,023	New	+$196K	0.03%	286
2015 Q2	–	Sell	-2,023	Closed	-$229K	–	304
2015 Q1	$229K	Hold	2,023	–	–	0.04%	266
2014 Q4	$233K	Buy	+2,023	New	+$213K	0.04%	256
2014 Q3	–	Sell	-2,023	Closed	-$204K	–	310
2014 Q2	$204K	Buy	+2,023	New	+$197K	0.05%	226

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Carnegie Investment Counsel's ZBH Position: Q2 2024 in Review

Carnegie Investment Counsel sold out of Zimmer Biomet (ZBH) in Q2 2024, closing a stake of 1,816 shares — an estimated $240K sold.

Carnegie Investment Counsel first reported a position in ZBH in Q2 2014 and held it in 11 quarters. The position peaked at $296K in Q3 2016. 1,005 funds tracked by Wall St. Rank hold ZBH as of Q2 2024.

Carnegie Investment Counsel reported no remaining Zimmer Biomet position as of Q2 2024 after selling out during the quarter.
Carnegie Investment Counsel sold 1,816 Zimmer Biomet shares in Q2 2024, an estimated $240K.
Carnegie Investment Counsel first reported a position in Zimmer Biomet in Q2 2014 and held it in 11 quarters.
Carnegie Investment Counsel's Zimmer Biomet position peaked at $296K in Q3 2016.
1,005 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2024.

Based on Carnegie Investment Counsel's 13F filing for Q2 2024, filed 22 Jul 2024.